Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

The maker of weight loss drugs Ozempic and Wegovy broke rules around the advertising and marketing of its medication to ...

Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call ... we are closely following potential tariffs on pharmaceutical products in the U.S. Before we move on to the particulars ...

MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...

Novo Nordisk was suspended by its own industry body in the UK for two years over its sponsorship of weight management courses ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...